title: The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.
abstract: BACKGROUND
  Recently, it is found that T-helper (Th) 22 cells are involved in different types of autoimmune and tumor diseases. But, till now, no study has been carried out to understand the involvement of these cells in cervical cancer (CC).
  
  
  METHODS
  Flow cytometry was used to determine the expression of interferon gamma (IFN-γ), Interleukin-22 (IL-22), IL-17 in the peripheral blood of healthy controls (HC), CIN and cervical cancer patients. From peripheral blood mononuclear cells (PBMCs), mRNA expression levels of Aryl hydrocarbon receptor (AHR), RAR-related orphan receptor C (RORC), TNF-α and IL-6 were respectively determined. Using the method of ELISA, plasma concentrations of IL-22, IL-17 and TNF-α were examined.
  
  
  RESULTS
  Th22 and Th17 cells were elevated in CC and CIN patients. Th1 cells and the plasma concentrations of IL-22 in CC patients were significantly increased compared with HC. In CC patients, an increased prevalence of Th22 cells was associated with lymph node metastases. There was a positive correlation between Th22 and Th17 cells, but an approximately negative correlation between Th22 and Th1 cells in CC patients. The mRNA expression of RORC, TNF-α and IL-6 was significantly high in CC patients.
  
  
  CONCLUSIONS
  Our results indicate that there is a higher circulatory frequency of Th22, Th17 and Th1 cells in CC which may conjointly participate in the pathogenesis and growth of CC.
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. zwj_med@163.com.|Key Laboratory of Gynecologic Oncology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. zwj_med@163.com.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 592128466@qq.com.|Hematology Oncology Center, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 592128466@qq.com.|Department of Obstetrics and Gynecology, Weifang Maternal and Child Health Hospital, Weifang, 261011, P.R. China. 592128466@qq.com.
authors.forename: Xinli
authors.initials: X
authors.lastname: Tian
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. fmumtahana@yahoo.com.
authors.forename: Fidia
authors.initials: F
authors.lastname: Mumtahana
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 731231865@qq.com.|Hematology Oncology Center, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 731231865@qq.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Jiao
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 402711821@qq.com.|Hematology Oncology Center, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. 402711821@qq.com.
authors.forename: Teng
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USA. kimiko@email.arizona.edu.
authors.forename: Kimiko Della
authors.initials: KD
authors.lastname: Croce
authors.affiliation: Hematology Oncology Center, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. daoxinma@sdu.edu.cn.
authors.forename: Daoxin
authors.initials: D
authors.lastname: Ma
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. kongbeihua@sdu.edu.cn.
authors.forename: Beihua
authors.initials: B
authors.lastname: Kong
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, P.R. China. cuibaoxia@sdu.edu.cn.
authors.forename: Baoxia
authors.initials: B
authors.lastname: Cui
mesh_terms: D000328:Adult; D002278:Carcinoma in Situ / Q000097:blood* / Q000235:genetics / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020381:Interleukin-17 / Q000096:biosynthesis / Q000097:blood; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood*; D007378:Interleukins / Q000096:biosynthesis / Q000097:blood; D008875:Middle Aged; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000096:biosynthesis / Q000097:blood*; D012333:RNA, Messenger / Q000097:blood; D018417:Th1 Cells / Q000378:metabolism / Q000473:pathology; D058504:Th17 Cells / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000235:genetics / Q000473:pathology; D000097043:Interleukin-22
chemical_list: D020381:Interleukin-17; D015850:Interleukin-6; D007378:Interleukins; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D000097043:Interleukin-22; C539900:RORC protein, human